Clinical Trial Results:
            A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Prognostic
Scoring System Low- or Intermediate-1-Risk  Myelodysplastic Syndrome
    
|     Summary | |
|     EudraCT number | 2011-000261-12 | 
|     Trial protocol | BE ES SE NL | 
|     Global completion date | 
                                    13 Sep 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    26 Aug 2016
                             | 
|     First version publication date | 
                                    26 Aug 2016
                             | 
|     Other versions | |
|     Summary report(s) | CNTO328MDS2001_2011-000261-12_CSR Synopsis | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
